Apr 29, 2019 - Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive first-quarter sales.
Apr 26, 2019 - Strong sales of Glaxo's (GSK) Vaccines segment is likely to drive the top line in the first quarter.
Apr 24, 2019 - On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.
Apr 24, 2019 - Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.
Apr 24, 2019 - During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.
Apr 23, 2019 - AstraZeneca (AZN) will report first-quarter results on Apr 26. New drugs likely to drive sales.
Apr 23, 2019 - Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 23, 2019 - The Zacks Analyst Blog Highlights: CommScope, Ceridian HCM, Cabot Oil & Gas, Incyte and Snap
Apr 22, 2019 - During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
Apr 22, 2019 - Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.